SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
Date of Report: March 30, 2000
BIORA AB
SE-205 12 Malmo, Sweden
Telephone: (011) 46-40-32-13-33
Indicate by a check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
|X| Form 20-F |_| Form 40-F
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
|_| Yes |X| No
If "Yes" is marked, indicate below the file number assigned to
the registrant in connection with Rule 12g3-2(b):
Not applicable.
This Form 6-K consists of a press release issued by Biora AB on
March 30, 2000 relating to the approval in Europe and Canada of a new
formulation of Biora's principal product, Emdogain(R).
BIORA'S NEW FORMULATION OF ITS PRINCIPAL PRODUCT, EMDOGAIN,(R)APPROVED IN
EUROPE AND CANADA
Biora's new formulation of its principal product Emdogain, named
Emdogain(R)Gel, has been approved for sale in Europe by BSI, British
Standards Institution, and in Canada by Health Canada (Sante Canada).
- - "According to our estimates this simplified way of using Emdogain will
stimulate sales in these markets", says Biora's CEO Tomas Hammargren.
Currently Emdogain is delivered as two components, a freeze-dried protein
and a vehicle solution, which the dentist is required to mix in order to
form a gel that can be drawn into a syringe and applied clinically.
To simplify handling and use, Biora will launch a completely new
formulation of Emdogain. With the new formulation and packaging,
Emdogain(R)Gel will be delivered as a stabilized premixed gel in a
prefilled syringe. Each syringe is for single use only and will be
individually packaged with a sterile outer layer in order to facilitate use
at the surgical field. The change in formulation, packaging and delivery
eliminates preparation time for the dentist and makes Emdogain truly ready
to use.
The product will be launched in Europe in the beginning of April. Biora
estimates that application for approval in the US market will be reviewed
during spring 2000.
- ------------------------------------------------------------------------------
Biora develops, manufactures and sells products for the treatment of
periodontal disease and for use in oral surgery. Using its proprietary
technology and expertise, Biora aims to become a world leader in
biology-based products for specialized dental therapy. Biora's American
Depository Shares are listed on the Nasdaq National Market in the US and
Biora's ordinary shares are listed on the "O-list" of the Stockholm Stock
Exchange in Sweden.
This report may contain certain forward-looking statements that relate to
future events or future business and financial performance. Such statements
can only be predictions and the actual events or results may differ from
those discussed. The Company cautions that these statements are subject to
important factors that could cause actual results to differ materially from
those expressed or implied in such forward-looking statements and are more
fully discussed in periodic reports filed with Securities and Exchange
Commission.
- ------------------------------------------------------------------------------
PRESIDENT AND CEO INVESTOR RELATIONS U.S INVESTOR RELATIONS
TOMAS HAMMARGREN MIKAEL SJOBLOM ELISABETH LAVERS
+46 40 32 13 36 + 46 40 32 13 65 203 977 7797
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
BIORA AB
Dated: March 30, 2000 By: /s/ Anders Agering
Anders Agering
Chief Financial Officer
